Fig. 7

CBR4 suppresses tumor growth via regulation of FASN in vivo. (A-F) Primary tumor samples were obtained from mice subcutaneously injected with RKO and SW480 cells, which were transfected with CBR4 over-expression and control cell groups (A, D). The relative tumor volumes (B, E) and weights (C, F) were measured at the endpoint. (G-I) Fluorescence intensity was assessed in a liver metastasis model with or without CBR4 over-expression. (J) Representative immunohistochemistry images illustrate the expression of CBR4, FASN, and Ki67 in both CBR4 over-expression and control groups, with a magnification of ×73. (K) Western blot analysis was conducted to examine mTOR and p-mTOR levels in CBR4 over-expression and control groups. (L-N) Primary tumor samples were also obtained from mice subcutaneously injected with HCT116 cells transfected with CBR4 knockdown, CBR4 knockdown + orlistat treatment, and control cell groups (L). The relative tumor volumes (M) and weights (N) were recorded at the endpoint. (O-P) The fluorescence intensity in the liver metastasis model was evaluated for CBR4 knockdown, CBR4 knockdown + orlistat treatment, and control cell groups. (Q) Representative immunohistochemistry images depict the expression of CBR4, FASN, and Ki67 in CBR4 down-regulation, CBR4 down-regulation + orlistat treatment, and control groups, with a magnification of ×73. (R) Western blot analysis was performed on mTOR and p-mTOR in CBR4 down-regulation, CBR4 down-regulation + orlistat treatment, and control groups. (**P < 0.01, ***P < 0.001)